Citigroup Inc Humacyte, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Humacyte, Inc. stock. As of the latest transaction made, Citigroup Inc holds 65,617 shares of HUMA stock, worth $279,528. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,617

Previous 31,421 108.83%

Holding current value

$279,528

Previous $150,000 137.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.11 - $9.46 $174,741 - $323,494	34,196 Added 108.83%	65,617 $356,000
Q2 2024 Aug 12, 2024	BUY	$2.87 - $9.1 $59,380 - $188,279	20,690 Added 192.81%	31,421 $150,000
Q1 2024 May 10, 2024	BUY	$2.57 - $4.84 $395 - $745	154 Added 1.46%	10,731 $33,000
Q4 2023 Feb 09, 2024	BUY	$1.99 - $3.12 $18,431 - $28,897	9,262 Added 704.33%	10,577 $30,000
Q3 2023 Nov 09, 2023	SELL	$2.75 - $4.48 $51,356 - $83,664	-18,675 Reduced 93.42%	1,315 $3,000
Q2 2023 Aug 10, 2023	BUY	$2.86 - $4.97 $53,810 - $93,510	18,815 Added 1601.28%	19,990 $57,000
Q1 2023 May 11, 2023	SELL	$2.11 - $3.25 $4,635 - $7,140	-2,197 Reduced 65.15%	1,175 $3,000
Q4 2022 Feb 09, 2023	BUY	$2.02 - $3.62 $472 - $847	234 Added 7.46%	3,372 $7,000
Q3 2022 Nov 10, 2022	SELL	$1.22 - $5.14 $1,279 - $5,391	-1,049 Reduced 25.05%	3,138 $10,000
Q2 2022 Aug 10, 2022	SELL	$3.21 - $7.86 $24,627 - $60,301	-7,672 Reduced 64.69%	4,187 $13,000
Q1 2022 May 12, 2022	BUY	$4.65 - $7.4 $36,237 - $57,668	7,793 Added 191.66%	11,859 $84,000
Q4 2021 Feb 10, 2022	BUY	$7.25 - $11.6 $29 - $46	4 Added 0.1%	4,066 $29,000
Q3 2021 Nov 10, 2021	BUY	$9.21 - $16.99 $37,411 - $69,013	4,062 New	4,062 $47,000

Others Institutions Holding HUMA

# of Institutions

160

Shares Held

35.8M

Call Options Held

284K

Put Options Held

607K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $439M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account